SUPERNUS PHARMACEUTICALS, INC. Marketable Securities (Non-Current)
SUPERNUS PHARMACEUTICALS, INC. (SUPN) had Marketable Securities (Non-Current) of $93.90 million as of 2022-12-31, per its 10-K filed 2023-03-09.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent › Long-Term Investments
us-gaap:MarketableSecuritiesNoncurrent · last filed 2023-03-09
- 2022-12-31: Marketable Securities, Noncurrent $93.90M.
- 2022-09-30: Marketable Securities, Noncurrent $131.94M.
- 2022-06-30: Marketable Securities, Noncurrent $147.37M.
- 2022-03-31: Marketable Securities, Noncurrent $125.34M.
| Period end | Marketable Securities, Noncurrent |
|---|---|
| 2022-12-31 | $93.90M 10-K · filed 2023-03-09 |
| 2022-09-30 | $131.94M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $147.37M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $125.34M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $119.17M 10-K · filed 2023-03-09 |
| 2021-09-30 | $405.48M 10-Q · filed 2021-11-05 |
| 2021-06-30 | $445.47M 10-Q · filed 2021-08-06 |
| 2021-03-31 | $416.57M 10-Q · filed 2021-05-07 |
| 2020-12-31 | $350.36M 10-K · filed 2022-04-13 |
| 2020-09-30 | $388.19M 10-Q · filed 2020-11-06 |
| 2020-06-30 | $358.67M 10-Q · filed 2020-08-17 |
| 2020-03-31 | $534.71M 10-Q · filed 2020-05-15 |
| 2019-12-31 | $591.77M 10-K · filed 2021-03-08 |
| 2019-09-30 | $596.44M 10-Q · filed 2019-11-08 |
| 2019-06-30 | $593.75M 10-Q · filed 2019-08-09 |
| 2019-03-31 | $522.55M 10-Q · filed 2019-05-10 |
| 2018-12-31 | $418.80M 10-K · filed 2020-02-28 |
| 2018-09-30 | $460.30M 10-Q · filed 2018-11-09 |
| 2018-06-30 | $503.31M 10-Q · filed 2018-08-09 |
| 2018-03-31 | $175.06M 10-Q · filed 2018-05-10 |
| 2017-12-31 | $133.64M 10-K · filed 2019-03-01 |
| 2017-09-30 | $123.12M 10-Q · filed 2017-11-09 |
| 2017-06-30 | $104.63M 10-Q · filed 2017-08-03 |
| 2017-03-31 | $89.16M 10-Q · filed 2017-05-09 |
| 2016-12-31 | $75.41M 10-K · filed 2018-03-01 |
| 2016-09-30 | $67.04M 10-Q · filed 2017-01-20 |
| 2016-06-30 | $67.81M 10-Q/A · filed 2017-01-23 |
| 2016-03-31 | $68.79M 10-Q/A · filed 2017-01-20 |
| 2015-12-31 | $55.01M 10-K · filed 2017-03-16 |
| 2015-09-30 | $43.97M 10-Q/A · filed 2017-01-20 |
| 2015-06-30 | $33.49M 10-Q/A · filed 2017-01-23 |
| 2015-03-31 | $27.32M 10-Q/A · filed 2017-01-20 |
| 2014-12-31 | $19.82M 10-Q/A · filed 2017-01-20 |
| 2014-09-30 | $15.76M 10-Q/A · filed 2017-01-20 |
| 2014-06-30 | $15.46M 10-Q · filed 2014-08-12 |
| 2014-03-31 | $11.66M 10-Q · filed 2014-05-13 |
| 2013-12-31 | $8.76M 10-Q · filed 2014-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |